At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
3 articles- Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy winBioSpace·2026-06-12
- Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual MeetingGlobeNewswire Biotech·2026-06-12press release
- <a href="https://www.fiercebiotech.com/biotech/novartis-data-tee-regulatory-talks-about-asset-12b-avidity-takeover" hreflang="en">Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover</a>FierceBiotech
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
MonitoRing the Effect of TRAnscutaneous Functional electrIcal Stimulation of the Common Peroneal Nerve on Cerebral Haemodynamics in Patients With Ischaemic Strokes. A Single Centre Prospective Study (Phase 1).
In Brief
An observational study for Ischaemic Stroke. Completed, enrolled 18 participants across 2 sites.
Detailed Summary
The primary objective is to investigate in stroke patients the impact of geko™ NMES treatment, when used as standard of care for VTE prevention, on brain haemodynamics at different stimulation levels and in three different postural positions (supine, semi-supine \[45° seated\] and seated). The aim is to identify the optimal stimulation level and postural position for the maximum response (NMES versus no NMES) with regard to relative total haemoglobin concentration (i.e., the sum of relative deoxyhaemoglobin and oxyhaemoglobin concentrations) using fNIRS and EEG.